Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

[Preprint] Systematic review: Characteristics of SARS-CoV-2 reinfection vs. persistent COVID-19

9 Mar, 2021 | 02:44h | UTC

SARS-CoV-2 Sequence Characteristics of COVID-19 Persistence and Reinfection – medRxiv

Commentary: How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection? – News Medical

 


Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice

7 Mar, 2021 | 19:20h | UTC

Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice – Heart

 


WHO: The effects of virus variants on COVID-19 vaccines

7 Mar, 2021 | 20:09h | UTC

The effects of virus variants on COVID-19 vaccines – World Health Organization

 


Some experience delayed rash after Moderna shot, study says

5 Mar, 2021 | 08:44h | UTC

Some Experience Delayed Rash After Moderna Shot, Study Says – Bloomberg

Original study: Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 – New England Journal of Medicine

 


A Review of Persistent Post-COVID Syndrome (PPCS)

4 Mar, 2021 | 08:45h | UTC

A Review of Persistent Post-COVID Syndrome (PPCS) – Clinical Reviews in Allergy & Immunology

 


NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms

3 Mar, 2021 | 08:55h | UTC

NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms – National Institutes of Health

 


The vaccine race against the coronavirus variants, explained

3 Mar, 2021 | 08:52h | UTC

The vaccine race against the coronavirus variants, explained – Vox

 


How to make ‘immunity passports’ more ethical

3 Mar, 2021 | 08:46h | UTC

How to Make ‘Immunity Passports’ More Ethical – Scientific American

Related: Twelve criteria for the development and use of COVID-19 vaccine passports

 


Expert consensus on practical aspects in the treatment of chronic urticaria

3 Mar, 2021 | 08:28h | UTC

Expert consensus on practical aspects in the treatment of chronic urticaria – Allergo Journal International

 


The predicative clinical features associated with chronic cough that has a single underlying cause

3 Mar, 2021 | 08:14h | UTC

The Predicative Clinical Features Associated with Chronic Cough That Has a Single Underlying Cause – The Journal of Allergy and Clinical Immunology: In Practice

News release: Clinical features for indicating causes of chronic cough – American Academy of Allergy, Asthma & Immunology

 


Another study shows higher antibody titer responses to a single dose of mRNA vaccine among patients with previous COVID-19 infection

2 Mar, 2021 | 02:13h | UTC

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 – JAMA

Related: Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection (studies and commentary)

 


Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

2 Mar, 2021 | 01:46h | UTC

Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge: a systematic review – JAC-Antimicrobial Resistance

 

Commentary on Twitter

 


M-A: Treatment with convalescent plasma is not associated with better outcomes in patients with Covid-19

28 Feb, 2021 | 21:51h | UTC

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis – JAMA

Editorial: Emerging Lessons From COVID-19 for the US Clinical Research Enterprise

 

Commentary on Twitter

 


Short Review: SARS-CoV-2 Vaccines

28 Feb, 2021 | 21:52h | UTC

SARS-CoV-2 Vaccines – JAMA

Author interview: Coronavirus Vaccines—An Overview

 

 


Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection

28 Feb, 2021 | 21:49h | UTC

Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection – Imperial College London

Study 1: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals – The Lancet

Study 2: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine – The Lancet

 

Commentary on Twitter (thread – click for more)

 


Spain to give just one vaccine dose to under 55-year olds who had COVID-19

28 Feb, 2021 | 21:47h | UTC

Spain to give just one vaccine dose to under 55-year olds who had COVID-19 – Reuters

Related: Is One Vaccine Dose Enough After COVID-19 Infection? – NIH Director’s Blog AND France’s health authority recommends single vaccine shot for people who have had COVID-19

 


Covid-19: In vitro studies show Pfizer-BioNTech and Moderna vaccines produce fewer antibodies against South African variant

19 Feb, 2021 | 03:01h | UTC

Study 1: Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report – New England Journal of Medicine

Study 2: Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report – New England Journal of Medicine

Commentaries: Expert reaction to two NEJM Correspondence articles on in vitro studies of the Pfizer-BioNTech and Moderna vaccines and different variants/mutations including mutations on the South Africa variant – Science Media Centre AND Lab studies suggest Pfizer, Moderna vaccines can protect against coronavirus variant – CNN AND Pfizer and Moderna vaccines have reduced effectiveness against South African variant, newly published studies show – The Washington Post AND Pfizer, Moderna vaccines less effective against South African COVID variant – MedicalXpress

 

Commentary on Twitter

 


A food allergy epidemic… or just another case of overdiagnosis?

19 Feb, 2021 | 02:13h | UTC

A food allergy epidemic… or just another case of overdiagnosis? – The BMJ Opinion

Original study: Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018 – The BMJ

 


Take whatever COVID vaccine you can get. All of them stop death and hospitalization

15 Feb, 2021 | 01:17h | UTC

Take whatever COVID vaccine you can get. All of them stop death and hospitalization – USA Today

“All seven COVID-19 vaccines that have completed large efficacy trials — Pfizer, Moderna, Johnson & Johnson, Novavax, AstraZeneca, Sputnik V and Sinovac — appear to be 100% effective for serious complications. Not one vaccinated person has gotten sick enough to require hospitalization. Not a single vaccinated person has died of COVID-19.”

 


Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US

15 Feb, 2021 | 01:13h | UTC

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021 – JAMA

Author interview: COVID-19 Vaccine Safety–Anaphylaxis and Allergic Reactions – JAMA

 

Commentary on Twitter

 


Small RCT: Inhaled budesonide reduces the need for hospitalization in COVID-19 patients

11 Feb, 2021 | 02:18h | UTC

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial – medRxiv

Commentaries: Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests – University of Oxford AND Expert reaction to preprint on an RCT of inhaled budesonide in the treatment of early COVID-19 – Science Media Centre

 


Perspective: Leave your antibodies alone

11 Feb, 2021 | 02:12h | UTC

Leave Your Antibodies Alone – The Atlantic

 


Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma

7 Feb, 2021 | 21:32h | UTC

SARS-CoV-2 evolution during treatment of chronic infection – Nature

 

Commentary on Twitter

 


German 2021 guideline update on acute therapy and management of anaphylaxis

4 Feb, 2021 | 01:17h | UTC

Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update – Allergo Journal International

 


UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus

4 Feb, 2021 | 01:32h | UTC

UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus – Biobank

Commentary: Covid: Antibodies last at least six months in most – BBC

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.